Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
LSTA
Valuation N/A
LISATA THERAPEUTICS, INC.
Price$1.63
Model IV—
P/IV—
Market implies +49.0%/yr
vs model +15.0% · above model
LTRN
Valuation N/A
Lantern Pharma Inc.
Price$1.70
Model IV—
P/IV—
LUCD
Deeply overvalued
Lucid Diagnostics Inc.
Price$0.78
Model IV$0.30
P/IV3.46
Premium +163%
Return to IV: -62.0%
Market implies +9.8%/yr
vs model +50.0% · below model
LUCY
Fairly valued
Innovative Eyewear Inc
Price$0.84
Model IV$0.95
P/IV1.10
Discount 12%
Return to IV: +13.2%
Market implies -0.4%/yr
vs model +40.1% · below model
LUCYW
Valuation N/A
Innovative Eyewear Inc
Price$0.04
Model IV—
P/IV—
Market implies -50.0%/yr
LUNG
Deeply overvalued
Pulmonx Corp
Price$1.85
Model IV$1.11
P/IV1.49
Premium +67%
Return to IV: -40.3%
Market implies +10.3%/yr
vs model +16.9% · below model
LXEO
Valuation N/A
Lexeo Therapeutics, Inc.
Price$4.25
Model IV—
P/IV—
Market implies +92.4%/yr
vs model +15.0% · above model
LXRX
Valuation N/A
LEXICON PHARMACEUTICALS, INC.
Price$2.00
Model IV—
P/IV—
Market implies +43.9%/yr
vs model +15.0% · above model
LYEL
Valuation N/A
Lyell Immunopharma, Inc.
Price$11.96
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
MAIA
Valuation N/A
MAIA Biotechnology, Inc.
Price$1.30
Model IV—
P/IV—
MANE
Valuation N/A
Veradermics, Inc
Price$103.89
Model IV—
P/IV—
MASI
Deeply overvalued
MASIMO CORP
Price$179.95
Model IV$57.69
P/IV3.09
Premium +212%
Return to IV: -67.9%
Owner yield 1.5%
10-yr IRR -8.7% · steady
Market implies +16.8%/yr
vs model +2.6% · above model
MASS
Valuation N/A
908 Devices Inc.
Price$9.52
Model IV—
P/IV—
Market implies +29.1%/yr
vs model +7.4% · above model
MAZE
Valuation N/A
Maze Therapeutics, Inc.
Price$24.23
Model IV—
P/IV—
Market implies +20.0%/yr
vs model +15.0% · above model
MBAI
Valuation N/A
Check-Cap Ltd
Price$6.49
Model IV—
P/IV—
MBIO
Valuation N/A
MUSTANG BIO, INC.
Price$0.50
Model IV—
P/IV—
MBOT
Valuation N/A
Microbot Medical Inc.
Price$1.45
Model IV—
P/IV—
MBRX
Valuation N/A
Moleculin Biotech, Inc.
Price$0.72
Model IV—
P/IV—
MBX
Valuation N/A
MBX Biosciences, Inc.
Price$59.49
Model IV—
P/IV—
MCRB
Valuation N/A
Seres Therapeutics, Inc.
Price$4.60
Model IV—
P/IV—
Market implies +82.6%/yr
vs model +2.0% · above model
MCTA
Valuation N/A
Charming Medical Ltd
Price$29.36
Model IV—
P/IV—
MD
Deeply undervalued
Pediatrix Medical Group, Inc.
Price$26.91
Model IV$43.64
P/IV0.49
Discount 38%
Return to IV: +62.2%
Market implies -4.9%/yr
vs model +3.0% · below model
MDAI
Deeply overvalued
Spectral AI, Inc.
Price$1.60
Model IV$0.82
P/IV2.54
Premium +96%
Return to IV: -49.0%
Market implies +6.4%/yr
vs model +15.0% · below model
MDAIW
Fairly valued
Spectral AI, Inc.
Price$0.53
Model IV$0.51
P/IV1.03
Premium +3%
Return to IV: -2.9%
Market implies -2.3%/yr
vs model +15.0% · below model
MDCX
Valuation N/A
Medicus Pharma Ltd.
Price$0.15
Model IV—
P/IV—
MDCXW
Valuation N/A
Medicus Pharma Ltd.
Price$0.32
Model IV—
P/IV—
MDGL
Deeply overvalued
MADRIGAL PHARMACEUTICALS, INC.
Price$523.26
Model IV$135.61
P/IV3.67
Premium +286%
Return to IV: -74.1%
Market implies +10.3%/yr
vs model +15.0% · below model
MDLN
Undervalued
Medline Inc.
Price$32.53
Model IV$47.28
P/IV0.77
Discount 31%
Return to IV: +45.3%
Owner yield 5.2%
10-yr IRR 12.1% · moderate
Market implies +3.5%/yr
vs model +10.4% · below model
MDT
Undervalued
Medtronic plc
Price$92.13
Model IV$108.65
P/IV0.68
Discount 15%
Return to IV: +17.9%
Owner yield 4.2%
10-yr IRR 5.8% · moderate
Market implies +3.1%/yr
vs model +6.1% · below model
MDWD
Valuation N/A
MediWound Ltd.
Price$13.47
Model IV—
P/IV—
MDXG
Deeply undervalued
MIMEDX GROUP, INC.
Price$4.72
Model IV$9.10
P/IV0.40
Discount 48%
Return to IV: +92.7%
Owner yield 7.8%
10-yr IRR 20.6% · grower
Market implies +0.9%/yr
vs model +13.3% · below model
MDXH
Valuation N/A
MDxHealth SA
Price$0.70
Model IV—
P/IV—
MEHA
Valuation N/A
Functional Brands Inc.
Price$0.00
Model IV—
P/IV—
Market implies +0.0%/yr
vs model +2.0% · in line
MENS
Valuation N/A
Jyong Biotech Ltd.
Price$1.99
Model IV—
P/IV—
MESO
Valuation N/A
MESOBLAST LTD
Price$15.48
Model IV—
P/IV—
MGNX
Deeply overvalued
MACROGENICS INC
Price$4.00
Model IV$2.64
P/IV1.57
Premium +51%
Return to IV: -33.9%
Market implies +3.8%/yr
vs model +17.9% · below model
MGRX
Deeply overvalued
MANGOCEUTICALS, INC.
Price$0.42
Model IV$0.13
P/IV3.37
Premium +229%
Return to IV: -69.6%
Market implies +18.0%/yr
vs model +50.0% · below model
MGTX
Valuation N/A
MeiraGTx Holdings plc
Price$12.76
Model IV—
P/IV—
Market implies +40.8%/yr
vs model +21.2% · above model
MGX
Valuation N/A
Metagenomi Therapeutics, Inc.
Price$1.16
Model IV—
P/IV—
Market implies +42.8%/yr
vs model +2.0% · above model
MIR
Valuation N/A
Mirion Technologies, Inc.
Price$15.98
Model IV—
P/IV—
Owner yield 1.7%
10-yr IRR -1.8% · moderate
Market implies +33.9%/yr
vs model +10.6% · above model
MIRA
Valuation N/A
MIRA PHARMACEUTICALS, INC.
Price$0.77
Model IV—
P/IV—
MIRM
Fairly valued
Mirum Pharmaceuticals, Inc.
Price$93.90
Model IV$97.88
P/IV1.04
Discount 4%
Return to IV: +4.2%
Market implies -2.0%/yr
vs model +50.0% · below model
MIST
Valuation N/A
Milestone Pharmaceuticals Inc.
Price$0.93
Model IV—
P/IV—
MKSI
Deeply overvalued
MKS INC
Price$267.31
Model IV$71.04
P/IV4.56
Premium +276%
Return to IV: -73.4%
Owner yield 2.1%
10-yr IRR -1.1% · moderate
Market implies +27.0%/yr
vs model +8.2% · above model
MLAB
Fairly valued
MESA LABORATORIES INC /CO/
Price$120.87
Model IV$96.97
P/IV1.05
Premium +25%
Return to IV: -19.8%
Owner yield 5.5%
10-yr IRR 15.6% · grower
Market implies +13.7%/yr
vs model +14.1% · in line
MLSS
Valuation N/A
MILESTONE SCIENTIFIC INC.
Price$0.44
Model IV—
P/IV—
Market implies +28.1%/yr
vs model +2.0% · above model
MLTX
Valuation N/A
MoonLake Immunotherapeutics
Price$12.20
Model IV—
P/IV—
MLYS
Valuation N/A
Mineralys Therapeutics, Inc.
Price$28.20
Model IV—
P/IV—
MMED
Valuation N/A
MiniMed Group, Inc.
Price$22.50
Model IV—
P/IV—
MMM
Deeply overvalued
3M CO
Price$165.89
Model IV$118.39
P/IV1.29
Premium +40%
Return to IV: -28.6%
Owner yield 5.8%
10-yr IRR 6.9% · steady
Market implies +6.4%/yr
vs model +2.0% · above model
MMSI
Undervalued
MERIT MEDICAL SYSTEMS INC
Price$86.36
Model IV$80.83
P/IV0.78
Premium +7%
Return to IV: -6.4%
Owner yield 3.3%
10-yr IRR 4.9% · moderate
Market implies +8.5%/yr
vs model +9.3% · in line
MNKD
Deeply undervalued
MANNKIND CORP
Price$3.56
Model IV$8.72
P/IV0.58
Discount 59%
Return to IV: +145.0%
Market implies -16.1%/yr
vs model +46.7% · below model
MNOV
Valuation N/A
MEDICINOVA INC
Price$1.81
Model IV—
P/IV—
Market implies +68.2%/yr
vs model +2.0% · above model
MNPR
Valuation N/A
Monopar Therapeutics
Price$104.33
Model IV—
P/IV—
MOBI
Valuation N/A
Mobia Medical, Inc.
Price$10.77
Model IV—
P/IV—
MODD
Valuation N/A
Modular Medical, Inc.
Price$2.41
Model IV—
P/IV—
MOLN
Valuation N/A
MOLECULAR PARTNERS AG
Price$4.18
Model IV—
P/IV—
MPLT
Valuation N/A
MapLight Therapeutics, Inc.
Price$13.00
Model IV—
P/IV—
MREO
Valuation N/A
Mereo BioPharma Group plc
Price$0.28
Model IV—
P/IV—
Market implies +36.1%/yr
vs model +15.0% · above model
MRK
Overvalued
Merck & Co., Inc.
Price$146.87
Model IV$120.25
P/IV1.20
Premium +22%
Return to IV: -18.1%
Owner yield 3.4%
10-yr IRR 4.6% · moderate
Market implies +9.2%/yr
vs model +8.2% · in line